nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
01220102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available… (More)
Is this relevant?
Review
2017
Review
2017
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the… (More)
  • table 1
Is this relevant?
2016
2016
Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the… (More)
  • table 1
  • table 2
  • table 4
  • table 3
  • table 5
Is this relevant?
Review
2011
Review
2011
Based on electrophysiological, neurochemical, genetic and neuropharmacological approaches, it is currently accepted that… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
5-Hydroxytryptamine (5-HT)(2A) receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2010
2010
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily… (More)
Is this relevant?